Biosimilars need a policy boost, experts say

by on

Policies should align with patients’ and providers’ growing support of biosimilars, but the therapies’ adoption has been slowed by patent litigation and price manipulation, industry observers said.

Policies should align with patients’ and providers’ growing support of biosimilars, but the therapies’ adoption has been slowed by patent litigation and price manipulation, industry observers said.

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: